Clinical & translational oncology

• 

  Año 2016, Vol. 18, Número 8 (August 2016)

  • Review Article

    • Review: circulating tumor cells in the practice of breast cancer oncology

      Rocío Ramos Medina, Fernando Moreno Antón, S. Lopez Tarruella, M. del Monte Millán, Iván Márquez Rodas, E. Durán, Yolanda Jerez Gilarranz, José Ángel García Sáenz, I. Ocaña, S. Andrés, T. Massarrah, M. González Rivera, Miguel Martín Jiménez

      • Resumen

      págs. 749-759

      

    • Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases

      Diego Márquez Medina, S. Popat

      • Resumen

      págs. 760-768

      

    • Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI)

      Enrique Grande Pulido, Francisco Javier Santamaría Sandi, Jaume Capdevila Castillon, Elena Navarro González, Carles Zafón Llopis, Teresa Ramón y Cajal, José Manuel Gómez Sáez, P. Jiménez Fonseca, Garcilaso Riesco Eizaguirre, Juan Carlos Galofré Ferrater

      • Resumen

      págs. 769-775

      

  • Research Article

    • ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker

      M.-J. Zhang, C.-Z. Zhang, W.-J. Du, X.-Z. Yang, Z.-P. Chen

      • Resumen

      págs. 776-781

      

    • Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer

      J.-G. Zhu, D.-B. Yuan, W.-H. Chen, Z.-D. Han, Y.-X. Liang, G. Chen, X. Fu, Y.-K. Liang, G.-X. Chen, Z.-L. Sun, Z.-Z. Liu, J.-H. Chen, F.-N. Jiang, W.-D. Zhong

      • Resumen

      págs. 782-791

      

    • Pin1 promotes prostate cancer cell proliferation and migration through activation of Wnt/β-catenin signaling

      Z. Zhu, H. Zhang, F. Lang, G. Liu, D. Gao, B. Li, Y. Liu

      • Resumen

      págs. 792-797

      

    • Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer

      Aránzazu Lafuente Sanchis, Angel Zúñiga, José Marcelo Galbis Caravajal, Antonio Cremades Mira, Miriam Estors Guerrero, Néstor Martínez Hernández, Julián Carretero Asunción

      • Resumen

      págs. 798-804

      

    • GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status

      Pedro Pérez Segura, R. Manneh, I. Ceballos, Almudena García Castaño, Manuel Benavides Orgaz, José Fuster Salvá, María Ángeles Vaz Salgado, Juana María Cano Cano, José Pablo Berros, M. Covela, Víctor Moreno García, M.T. Quintanar Verdúguez, José María García Bueno, I. Fernández Pérez, Juan Manuel Sepúlveda Sánchez

      • Resumen

      págs. 805-812

      

    • CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review

      G. Colloca, A. Venturino, I. Governato

      • Resumen

      págs. 813-824

      

    • Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer

      Miguel Martín Jiménez, A. Hinojar, Laura Cerezo Padellano, J. García, M. Lopez, J. Prada, Alicia Marín Palomo, Carlos Gamallo Amat

      • Resumen

      págs. 825-830

      

    • Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients

      T. T. Zhang, X. Q. Zhao, Z. Liu, Z. Y. Mao, L. Bai

      • Resumen

      págs. 831-840

      

    • Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance

      L. Yang, Q. Xu, H. Xie, G. Gu, J. Jiang

      • Resumen

      págs. 841-847

      

  • Brief Research Article

    • Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data

      Omar Mohammed Abdel-Rahman, H. ElHalawani, H. Ahmed

      • Resumen

      págs. 848-858

      

  • Correspondence

    • Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients

      J. Giuliani, A. Mercanti, A. Bonetti

      págs. 859-862